Suppr超能文献

透析合并甲状旁腺功能亢进患者的甲状旁腺超声检查及骨代谢指标

Parathyroid ultrasonography and bone metabolic profile of patients on dialysis with hyperparathyroidism.

作者信息

Ribeiro Cláudia, Penido Maria Goretti Moreira Guimarães, Guimarães Milena Maria Moreira, Tavares Marcelo de Sousa, Souza Bruno das Neves, Leite Anderson Ferreira, de Deus Leonardo Martins Caldeira, Machado Lucas José de Campos

机构信息

Cláudia Ribeiro, Center of Nephrology, Santa Casa de Belo Horizonte Hospital, Belo Horizonte CEP 30150320, Minas Gerais, Brazil.

出版信息

World J Nephrol. 2016 Sep 6;5(5):437-47. doi: 10.5527/wjn.v5.i5.437.

Abstract

AIM

To evaluate the parathyroid ultrasonography and define parameters that can predict poor response to treatment in patients with secondary hyperparathyroidism due to renal failure.

METHODS

This cohort study evaluated 85 patients with chronic kidney disease stage V with parathyroid hormone levels above 800 pg/mL. All patients underwent ultrasonography of the parathyroids and the following parameters were analyzed: Demographic characteristics (etiology of chronic kidney disease, gender, age, dialysis vintage, vascular access, use of vitamin D), laboratory (calcium, phosphorus, parathyroid hormone, alkaline phosphatase, bone alkaline phosphatase), and the occurrence of bone changes, cardiovascular events and death. The χ(2) test were used to compare proportions or the Fisher exact test for small sample frequencies. Student t-test was used to detect differences between the two groups regarding continuous variables.

RESULTS

Fifty-three patients (66.4%) had parathyroid nodules with higher levels of parathyroid hormone, calcium and phosphorus. Sixteen patients underwent parathyroidectomy and had higher levels of phosphorus and calcium × phosphorus product (P = 0.03 and P = 0.006, respectively). They also had lower mortality (32% vs 68%, P = 0.01) and lower incidence of cardiovascular or cerebrovascular events (27% vs 73%, P = 0.02). Calcium × phosphorus product above 55 mg(2)/dL(2) [RR 1.48 (1.06, 2.08), P = 0.03], presence of vascular calcification [1.33 (1.01, 1.76), P = 0.015] and previous occurrence of vascular events [RR 2.25 (1.27, 3.98), P < 0.001] were risk factors for mortality in this population. There was no association between the occurrence of nodules and mortality.

CONCLUSION

The identification of nodules at ultrasonography strengthens the indication for parathyroidectomy in patients with secondary hyperparathyroidism due to renal failure.

摘要

目的

评估甲状旁腺超声检查,并确定可预测因肾衰竭导致的继发性甲状旁腺功能亢进患者治疗反应不佳的参数。

方法

这项队列研究评估了85例慢性肾脏病Ⅴ期且甲状旁腺激素水平高于800 pg/mL的患者。所有患者均接受了甲状旁腺超声检查,并分析了以下参数:人口统计学特征(慢性肾脏病病因、性别、年龄、透析时间、血管通路、维生素D的使用情况)、实验室检查指标(钙、磷、甲状旁腺激素、碱性磷酸酶、骨碱性磷酸酶),以及骨改变、心血管事件和死亡的发生情况。采用χ²检验比较比例,对于小样本频率采用Fisher精确检验。采用Student t检验检测两组在连续变量方面的差异。

结果

53例患者(66.4%)有甲状旁腺结节,其甲状旁腺激素、钙和磷水平较高。16例患者接受了甲状旁腺切除术,其磷水平和钙×磷乘积较高(分别为P = 0.03和P = 0.006)。他们的死亡率也较低(32%对68%,P = 0.01),心血管或脑血管事件的发生率也较低(27%对73%,P = 0.02)。钙×磷乘积高于55 mg²/dL²[相对危险度1.48(1.06,2.08),P = 0.03]、存在血管钙化[1.33(1.01,1.76),P = 0.015]以及既往发生血管事件[相对危险度2.25(1.27,3.98),P < 0.001]是该人群死亡的危险因素。结节的出现与死亡率之间无关联。

结论

超声检查发现结节可加强对因肾衰竭导致的继发性甲状旁腺功能亢进患者进行甲状旁腺切除术的指征。

相似文献

3
General weakness as an indication for parathyroid surgery in patients with secondary hyperparathyroidism.
Arch Surg. 1999 Oct;134(10):1108-11. doi: 10.1001/archsurg.134.10.1108.
4
Posterior urethral valves: Metabolic consequences in a cohort of patients.
J Pediatr Urol. 2015 Aug;11(4):216.e1-6. doi: 10.1016/j.jpurol.2015.04.022. Epub 2015 Jun 4.
7
Spermatogenesis after parathyroidectomy in patients with symptomatic secondary hyperparathyroidism.
J Am Coll Surg. 2003 Jun;196(6):854-8. doi: 10.1016/S1072-7515(03)00129-7.
10
A practical self-made device in parathyroid autotransplantation for patients with secondary hyperparathyroidism.
J Int Med Res. 2019 Jan;47(1):59-65. doi: 10.1177/0300060518794840. Epub 2018 Sep 9.

本文引用的文献

1
Klotho/FGF23 Axis in CKD.
Contrib Nephrol. 2015;185:56-65. doi: 10.1159/000380970. Epub 2015 May 19.
2
Current status of parathyroidectomy for secondary hyperparathyroidism in Japan.
NDT Plus. 2008 Aug;1(Suppl 3):iii35-iii38. doi: 10.1093/ndtplus/sfn085.
3
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Cochrane Database Syst Rev. 2014;2014(12):CD006254. doi: 10.1002/14651858.CD006254.pub2. Epub 2014 Dec 9.
4
What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?
Curr Opin Nephrol Hypertens. 2013 Nov;22(6):651-5. doi: 10.1097/MNH.0b013e328365b3a3.
5
Phosphate homeostasis and its role in bone health.
Pediatr Nephrol. 2012 Nov;27(11):2039-2048. doi: 10.1007/s00467-012-2175-z. Epub 2012 May 3.
6
9
FGF23 and the parathyroid glands.
Pediatr Nephrol. 2010 Nov;25(11):2241-5. doi: 10.1007/s00467-010-1565-3. Epub 2010 Jun 5.
10
Plasma parathyroid hormone and the risk of cardiovascular mortality in the community.
Circulation. 2009 Jun 2;119(21):2765-71. doi: 10.1161/CIRCULATIONAHA.108.808733. Epub 2009 May 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验